Healthcare stocks were mixed Friday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.3%.
The iShares Biotechnology ETF (IBB) was up 0.1%.
In corporate news, Intuitive Surgical (ISRG) shares fell past 12%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.
GSK (GSK) shares were down 2.7% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.
Takeda Pharmaceutical (TAK) shares rose 2%. The company said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.